| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
The Journal of Thoracic and Cardiovascular Surgery, Vol 72, 127-129, Copyright © 1976 by The American Association for Thoracic Surgery and The Western Thoracic Surgical Association
R Altman, F Boullon, J Rouvier, R Raca, L de la Fuente and R Favaloro
Anticoagulation therapy with acenocoumarin or with anticoagulants plus
aspirin was given to 65 and 57 patients, respectively, with cardiac valve
replacement. The follow-up was 1,462 months (22.5 months per patient) for
the first group and 1,411 months (24.7 months per patient) for the second
group. The frequency of embolic accidents was significantly lower in the
group taking aspirin: Thirteen thromboembolic accidents were detected in
patients receiving the anticoagulant and 3 in the group receiving the
anticoagulant plus aspirin. These figures represent a 20.3 per cent
incidence (one each 9.3 years of treatment) for the anticoagulant group and
a 5.2 per cent incidence (one accident each 39.1 years of treatment) for
the other group. The statistical significance between groups is p less than
0.005. There was no difference in the hemorrhagic risk between the two
groups. We conclude that the use of an anticoagulant plus aspirin is a good
and safe therapy for the prevention of thromboembolism in these patients.
ARTICLES
Aspirin and prophylaxis of thromboembolic complications in patients with substitute heart valves
This article has been cited by other articles:
|
|
 |
|
  2006 WRITING COMMITTEE MEMBERS, R. O. Bonow, B. A. Carabello, K. Chatterjee, A. C. de Leon Jr, D. P. Faxon, M. D. Freed, W. H. Gaasch, B. W. Lytle, R. A. Nishimura, et al. 2008 Focused Update Incorporated Into the ACC/AHA 2006 Guidelines for the Management of Patients With Valvular Heart Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1998 Guidelines for the Management of Patients With Valvular Heart Disease): Endorsed by the Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons Circulation, October 7, 2008; 118(15): e523 - e661. [Full Text] [PDF]
|
|
|
|
 |
|
 R. O. Bonow, B. A. Carabello, K. Chatterjee, A. C. de Leon Jr, D. P. Faxon, M. D. Freed, W. H. Gaasch, B. W. Lytle, R. A. Nishimura, P. T. O'Gara, et al. 2008 Focused Update Incorporated Into the ACC/AHA 2006 Guidelines for the Management of Patients With Valvular Heart Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1998 Guidelines for the Management of Patients With Valvular Heart Disease) Endorsed by the Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons J. Am. Coll. Cardiol., September 23, 2008; 52(13): e1 - e142. [Full Text] [PDF]
|
|
|
|
 |
|
 C. Patrono, C. Baigent, J. Hirsh, and G. Roth Antiplatelet Drugs: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition) Chest, June 1, 2008; 133(6_suppl): 199S - 233S. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Schulman, R. J. Beyth, C. Kearon, and M. N. Levine Hemorrhagic Complications of Anticoagulant and Thrombolytic Treatment: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition) Chest, June 1, 2008; 133(6_suppl): 257S - 298S. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Patrono and B. Rocca Aspirin: Promise and Resistance in the New Millennium Arterioscler. Thromb. Vasc. Biol., March 1, 2008; 28(3): s25 - s32. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Dentali, J. D. Douketis, W. Lim, and M. Crowther Combined Aspirin-Oral Anticoagulant Therapy Compared With Oral Anticoagulant Therapy Alone Among Patients at Risk for Cardiovascular Disease: A Meta-analysis of Randomized Trials Arch Intern Med, January 22, 2007; 167(2): 117 - 124. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. O. Bonow, B. A. Carabello, K. Chatterjee, A. C. de Leon Jr, D. P. Faxon, M. D. Freed, W. H. Gaasch, B. W. Lytle, R. A. Nishimura, P. T. O'Gara, et al. ACC/AHA 2006 Guidelines for the Management of Patients With Valvular Heart Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1998 Guidelines for the Management of Patients With Valvular Heart Disease) Developed in Collaboration With the Society of Cardiovascular Anesthesiologists Endorsed by the Society for Cardiovascular Angiography and Interventions and the Society of Thoracic Surgeons J. Am. Coll. Cardiol., August 1, 2006; 48(3): e1 - e148. [Full Text] [PDF]
|
|
|
|
 |
|
 R. G. Hart, S. B. Tonarelli, and L. A. Pearce Avoiding Central Nervous System Bleeding During Antithrombotic Therapy: Recent Data and Ideas Stroke, July 1, 2005; 36(7): 1588 - 1593. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Perez-Gomez, E. Alegria, J. Berjon, J. A. Iriarte, J. Zumalde, A. Salvador, L. Mataix, and NASPEAF Investigators Comparative effects of antiplatelet, anticoagulant, or combined therapy in patients with valvular and nonvalvular atrial fibrillation: A randomized multicenter study J. Am. Coll. Cardiol., October 19, 2004; 44(8): 1557 - 1566. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Patrono, B. Coller, G. A. FitzGerald, J. Hirsh, and G. Roth Platelet-Active Drugs: The Relationships Among Dose, Effectiveness, and Side Effects: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy Chest, September 1, 2004; 126(3_suppl): 234S - 264S. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. N. Levine, G. Raskob, R. J. Beyth, C. Kearon, and S. Schulman Hemorrhagic Complications of Anticoagulant Treatment: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy Chest, September 1, 2004; 126(3_suppl): 287S - 310S. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Massel and S. H. Little Risks and benefits of adding anti-platelet therapy to warfarin among patients with prosthetic heart valves: a meta-analysis J. Am. Coll. Cardiol., February 1, 2001; 37(2): 569 - 578. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Patrono, B. Coller, J. E. Dalen, G. A. FitzGerald, V. Fuster, M. Gent, J. Hirsh, and G. Roth Platelet-Active Drugs : The Relationships Among Dose, Effectiveness, and Side Effects Chest, January 1, 2001; 119(1_suppl): 39S - 63S. [Full Text] [PDF]
|
|
|
|
|
|
M. N. Levine, G. Raskob, S. Landefeld, and C. Kearon Hemorrhagic Complications of Anticoagulant Treatment Chest, January 1, 2001; 119(1_suppl): 108S - 121S. [Full Text] [PDF]
|
|
|
|
|
|
P. Laffort, R. Roudaut, X. Roques, S. Lafitte, C. Deville, J. Bonnet, and E. Baudet Early and long-term (one-year) effects of the association of aspirin and oral anticoagulant on thrombi and morbidity after replacement of the mitral valve with the st. jude medical prosthesis: A clinical and transesophageal echocardiographic study J. Am. Coll. Cardiol., March 1, 2000; 35(3): 739 - 746. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J.-P. Bossavy, K. S. Sakariassen, C. Thalamas, B. Boneu, and Y. Cadroy Antithrombotic Efficacy of the Vitamin K Antagonist Fluindione in a Human Ex Vivo Model of Arterial Thrombosis : Effect of Anticoagulation Level and Combination Therapy With Aspirin Arterioscler. Thromb. Vasc. Biol., September 1, 1999; 19(9): 2269 - 2275. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Altman Controversies in Antithrombotic Therapy in Cardiovascular Diseases Clinical and Applied Thrombosis/Hemostasis, January 1, 1998; 4(1): 11 - 24. [Abstract] [PDF]
|
|
|
|
|
|
W. F. Baker JR Thrombosis and Hemostasis in Cardiology: Review of Pathophysiology and Clinical Practice (Part I) Clinical and Applied Thrombosis/Hemostasis, January 1, 1998; 4(1): 51 - 75. [Abstract] [PDF]
|
|
|
|
 |
|
 S. S. Meschengieser, C. G. Fondevila, J. Frontroth, M. T. Santarelli, and M. A. Lazzari LOW-INTENSITY ORAL ANTICOAGULATION PLUS LOW-DOSE ASPIRIN VERSUS HIGH-INTENSITY ORAL ANTICOAGULATION ALONE: A RANDOMIZED TRIAL IN PATIENTS WITH MECHANICAL PROSTHETIC HEART VALVES J. Thorac. Cardiovasc. Surg., May 1, 1997; 113(5): 910 - 916. [Abstract] [Full Text]
|
|
|
|
|
|
G. Franco Gensini, A. Colella, and M. Comeglio State-of-the-Art Review: Antiplatelet Agents and Thrombin Inhibitors: Combined Modality Therapy Clinical and Applied Thrombosis/Hemostasis, April 1, 1997; 3(2): 82 - 85. [PDF]
|
|
|
|
|
|
R. Altman, J. Rouvier, E. Gurfinkel, A. Scazziota, and A. G.G. Turpie Comparison of High-Dose With Low-Dose Aspirin in Patients With Mechanical Heart Valve Replacement Treated With Oral Anticoagulant Circulation, November 1, 1996; 94(9): 2113 - 2116. [Abstract] [Full Text]
|
|
|
|
 |
|
 W. Vongpatanasin, L. D. Hillis, and R. A. Lange Prosthetic Heart Valves N. Engl. J. Med., August 8, 1996; 335(6): 407 - 416. [Full Text] [PDF]
|
|
|
|
|
|
R. G. Hart, B. S. Boop, and D. C. Anderson Oral Anticoagulants and Intracranial Hemorrhage : Facts and Hypotheses Stroke, August 1, 1995; 26(8): 1471 - 1477. [Abstract] [Full Text]
|
|
|
|
 |
|
 Antiplatelet Trialists Collaborative overview of randomised trials of antiplatelet therapy Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients BMJ, January 8, 1994; 308(6921): 81 - 106. [Abstract] [Full Text]
|
|
|
|
|
|
M. H. Eckman, H. J. Levine, and S. G. Pauker Effect of Laboratory Variation in the Prothrombin-Time Ratio on the Results of Oral Anticoagulant Therapy N. Engl. J. Med., September 2, 1993; 329(10): 696 - 702. [Abstract] [Full Text]
|
|
|
|
|
|
A. Turpie, M. Gent, A. Laupacis, Y. Latour, J. Gunstensen, F. Basile, M. Klimek, and J. Hirsh A Comparison of Aspirin with Placebo in Patients Treated with Warfarin after Heart-Valve Replacement N. Engl. J. Med., August 19, 1993; 329(8): 524 - 529. [Abstract] [Full Text]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| ANN THORAC SURG | ASIAN CARDIOVASC THORAC ANN | EUR J CARDIOTHORAC SURG |
| J THORAC CARDIOVASC SURG | ICVTS | ALL CTSNet JOURNALS |
